Best-Aguilera CR, Fernández-Figueroa YM, Robles-Rodríguez A, López-Hernández JC, Guzmán-Hernández AE

Language: Spanish
References: 17
Page: 133-140
PDF size: 327.17 Kb.

ABSTRACT

The arrival of the tyrosine kinase inhibitors (TKI) to the clinical setting is a milestone in the treatment of chronic myeloid leukemia; however, a significant group of patients do not reach any benefit from this therapy, and also it has not proven to definitively eradicate the Philadelphia + leukemic stem cell (LSC). Consequently there is an active research on several fronts of the tumor biology that involves the signaling pathways for survival and proliferation, immune response and the protective niche of the LSC Ph+. In this paper, we review these areas and also some considerations about the present and future strategies for the definitive cure of the disease.

REFERENCES

1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973;243:290- 293.

2. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357:258-65.

3. No authors listed. Ariad suspends ponatinib sales. Cancer discov 2014;6.

4. Mahon FX, Réa D, Guilhot J, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 No v;11(11):1029-35.

5. Warsch W, Walz C, Sexl V. JAK of all trades: JAK2-STAT5 as a novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 2013;122(13):2167-2175.

6. Sinclair A, Latif A L, Holyoake T L, Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol 2013;169:1693-1707.

7. Ahmed Wesam, Van Etten Richard A. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine- kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program 2013;189-200.

8. Yang Ke, Fu Li-wu. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review. Crit Rev Oncol/Hematol 2015;277-292.

9. Talpaz M, Hehlmann R, Quintás-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia 2013;27:803-812.

10. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010 Dec 23;363(26):2511-21.

11. Sharpe M, Mount N. Genetically modified T cells in cancer therapy: opportunities and challenges. Disease Models & Mechanisms 2015;337-350.

12. Jabbour E. Chronic myeloid leukemia- What else is there beyond protein kinasa inhibitors? Oncol Hematol Rev 2014;97-102.

13. Chen Y, Li S. Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. Onco Targets and therapy 2014;7:177-186.

14. Aristizabal JA, Chandia M, Del Cañizo MC, Sánchez-Guijo F. Microambiente medular en la leucemia mieloide crónica: su relación con la enfermedad y la respuesta al tratamiento. Rev Med Chile 2014;142:599-605.

15. Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012;26(5):985-990.

16. Drummond MW, Heaney N, Kaeda J, et al. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia 2009;23(6):1199-1201.

17. Dobrovinskaya O, Delgado-Enciso I, Quintero-Castro LJ, Best-Aguilera CR, et al. Placing ion channels into a signaling network of T cells: from maturing thymocytes to healthy T lymphocytes or leukemic T lymphoblasts. Biomed Res Int 2015;2015:750203.